Author

E. Felley-Bosco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

B. Vrugt· 2 shared H. Rehrauer· 2 shared L. Wu· 2 shared M. de Perrot· 2 shared M. Ronner· 2 shared V. Serre-Beinier· 2 shared A. Hariharan· 1 shared A. Okonska· 1 shared

Activity by Year

2017-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Vrugt

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivJul 12, 2022

Heterogeneity of RNA editing in mesothelioma and how RNA editing enzyme ADAR2 affects mesothelioma cell growth, response to chemotherapy and tumor microenvironment

A. Hariharan, W. Qi, H. Rehrauer…·E. Felley-Bosco

This study examines RNA editing heterogeneity in mesothelioma and shows ADAR2's role in cell growth, chemotherapy response, and tumor microenvironment regulation.

DOI 10.1002/1878-0261.13322

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivJul 31, 2018

Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapy

A. Okonska, S. Buehler, V. Rao…·E. Felley-Bosco

The paper identifies BAP1's role in regulating RRM2 during replication stress, showing that BAP1 loss increases chemoresistance to ribonucleotide reductase inhibitors in mesothelioma cells.

DOI 10.1158/1535-7163.mct-19-0356

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivAug 31, 2017

How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing and somatic mutations

H. Rehrauer, L. Wu, W. Blum…·E. Felley-Bosco

This study shows asbestos exposure triggers YAP/TAZ activation, macrophage recruitment, and RNA editing in mesothelium before tumor development.

DOI 10.1038/s41388-018-0153-z

mousebulk RNA-seq

𝕏 PostBluesky